Share this article on:

Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups

Braibant, Martinea; Gong, Eun-Yeunga,*; Plantier, Jean-Christophec; Moreau, Thierryd; Alessandri, Elodiec; Simon, Françoise; Barin, Francisa,b

doi: 10.1097/QAD.0b013e32835ecb42
Basic Science: Concise Communication

Objective: HIV-1 has been classified into four groups: M, N, O and P. The aim of this study was to revisit the cross-group neutralization using a highly diverse panel of primary isolates.

Design: The panel of viruses included nine HIV-1 group O primary isolates, one recombinant M/O primary isolate, one group N primary isolates, one group P primary isolate, two group M (subtype B) primary isolates and the HIV-1 group M adapted strain MN.

Methods: All the viruses were tested for neutralization in TZM-bl cells, using sera issued from patients infected by viruses of group M (n = 11), O (n = 12) and P (n = 1), and a panel of nine human monoclonal broadly neutralizing antibodies (HuMo bNAbs).

Results: Although the primary isolates displayed a wide spectrum of sensitivity to neutralization by the human sera, cross-group neutralization was clearly observed. In contrast, the bNAbs did not show any cross-group neutralization, except PG9 and PG16. Interestingly, the group N prototype strain YBF30 was highly sensitive to neutralization by PG9 (IC50: 0.28 μg/ml) and PG16 (IC50: < 0.12 μg/ml). The interaction between PG9 and key residues of YBF30 was confirmed by molecular modeling.

Conclusion: The conservation of the PG9 and PG16 epitopes within groups M and N provides an argument for their relevance as components of a potentially efficient HIV vaccine immunogen.

Supplemental Digital Content is available in the text

aUniversité François-Rabelais - Inserm U966

bLaboratoire de Bactériologie-Virologie, CHU Bretonneau, Tours

cUniversité de Rouen and CHU Charles Nicolle, Rouen

dUniversité François Rabelais - Inserm U1100, Tours

eLaboratoire de Virologie, Hôpital Saint-Louis, Paris, France.

*Present address: The Beatson Institute for Cancer Research, Switchback Road, Bearsden, G61 1BD, Glasgow, UK.

Correspondence to Dr Francis Barin, Laboratoire de Virologie, CHU Bretonneau, 37044, Tours Cedex, France. Tel: +33 2 4747 8058; fax: +33 2 4747 3610; e-mail:

Received 3 November, 2012

Revised 17 December, 2012

Accepted 9 January, 2013

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (

Back to Top | Article Outline


Despite two decades of vaccine research efforts, the discovery of an immunogen able to induce broadly neutralizing antibodies (bNAbs) that mediate potent cross-clade neutralizing activity, has not been reached yet [1–4]. However, recent findings have inspired optimism and might have paved the way to reach this goal. First, it has become clear that some HIV-1-infected individuals develop bNAbs [5,6]. This means that the relevant epitope(s) exist toward which a specific response can be mounted, at least in some individuals. Second, the results of passive immunization experiments in animal models have demonstrated that human monoclonal bNAbs (b12, 2G12, 2F5, 4E10) can fully protect from HIV-1 infection [7–12]. Third, the association of several technological advances recently allowed the identification of highly potent human monoclonal (HuMo) bNAbs (particularly the PG, PGT and VRC series) that are 10-fold to 100-fold more potent than the HuMo bNAbs cited above [13–16]. Interestingly enough, several studies suggested that broad and potent serum neutralizing activity in most of the patients with bNAbs arises through a limited number of specificities that correspond to the targets of the human monoclonal bNAbs [17–20].

All the concepts and studies described above concerned HIV-1 of group M. HIV-1 has been classified into four groups, M, N, O and P [21–25]. HIV-1 group M has spread worldwide and is responsible for the AIDS pandemic, whereas variants of the other groups remained restricted geographically to their region of emergence from wild reservoirs, mainly Cameroon, and have a much lower epidemiological burden [23,24,26–33]. Although highly divergent, a few studies using a limited number of group O isolates have suggested that neutralizing epitopes might be conserved between group M and group O [34–36]. Such intergroup conserved neutralizing epitopes would be ideal components for an AIDS vaccine that would induce bNAbs. The aim of our study was to revisit the intergroup neutralization based on a large panel of viruses representative of the divergent groups M, O, N and P, and the identification of new highly potent HuMo bNAbs.

Back to Top | Article Outline


Virus isolates

Twelve HIV-1 strains related to groups O, N and P were used (see table, Supplemental Digital Content 1,, which describes their characteristics). In addition, we included three group M (subtype B) viruses. The MN strain was used as a prototype of T-cell line adapted variant highly sensitive to neutralization (tier 1). The two other M viruses (FRO, BIG) were primary isolates with moderate or low sensitivity to neutralization (tier 2–3) [37]. The virus stocks for the neutralization assays were prepared as described [37].

Back to Top | Article Outline

Serum samples

Twelve sera were obtained from patients infected by HIV-1 group O variants [38], one serum from a group P-infected patient (RBF168) [23] and 10 sera from group M infected blood donors, including two sera (H112 and H285) previously identified as having bNAbs (unpublished data) (Table 1). In addition a broadly neutralizing serum issued from a clade B-infected elite neutralizer (LTNP 08003) was used [5].

Table 1

Table 1

Back to Top | Article Outline

Neutralization assay

Neutralization assays were performed as described [39] using 100 TCID50 of each virus and three-fold serial dilutions of each heat-inactivated serum (starting at 1/20) or of each HuMo bNAbs (starting at 50 μg/ml for b12, 2G12, 2F5 and 4E10, and at 10 μg/ml for PG9, PG16, VRC01, VRC03 and HJ16). The results were expressed as the mean values of the assays performed in duplicate.

Back to Top | Article Outline

Sequence analysis and structural modeling

V1/V2 sequence alignments were performed using Clustal W from the BioEdit package ( On the basis of the sequence homology of YBF30 with CAP45, the recently defined structure of the V1/V2 domain of HIV-1 gp120 in complex with PG9 [40] was used to model the structure of the YBF30 V1/V2-PG9 complex (see legend of figure, Supplemental Digital Content 2,, that describes the structural modeling).

Back to Top | Article Outline


Cross-group neutralization by human sera

Although the human sera displayed a wide heterogeneity of neutralizing activity, cross-group neutralization was clearly observed (Table 1). On the basis of the IC50 values, six, four, one and four of the 12 group O sera cross-neutralized, respectively, the tier two group M strain FRO, the tier 1 group M strain MN, the group N strain YBF30 and the group P strain RBF168. Sera from the group M elite neutralizer (LTNP 08003) and H285 presented a neutralizing activity against all the viruses tested. Three other M sera (H112, H122, H154) cross-neutralized from four to six group O primary isolates, the group N strain and, except H154, the group P strain. Interestingly enough, the three group M sera that neutralized the three M strains showed the broadest cross-neutralization activity (H112, H285 and LTNP 08003). The serum from the group P patient (RBF168) did not show any neutralizing activity, including autologous neutralization.

Back to Top | Article Outline

Cross-group neutralization by human monoclonal broadly neutralizing antibodies

The HuMo bNAbs did not show any cross-group neutralization, except PG9 and PG16. Two groups O primary isolates (BCF02 and RBF189; Table 1 and Fig. 1a) were neutralized by both PG9 and PG16 (IC50: 0.23–7.62 μg/ml), and one group O primary isolate (BCF03) was neutralized by PG9 only (IC50: 9.39 μg/ml). However, their neutralization sensitivity was low since the IC90 was detectable only for PG9 and for only one primary isolate (BCF02). In contrast, the group N primary isolate (YBF30) was highly sensitive to neutralization by PG9 (IC50: 0.28 μg/ml; IC90: 4.28 μg/ml) and PG16 (IC50: <0.12 μg/ml; IC90: 4.99 μg/ml) (Table 1). The intergroup M/O recombinant strain RBF208 was sensitive to neutralization by 2F5 and VRC01. It can be easily explained by the fact that the env gene of this recombinant strain is related to group M.

Fig. 1

Fig. 1

Back to Top | Article Outline

Conservation of residues involved in the PG9 epitope

To try to understand the molecular basis of viral sensitivity or resistance to PG9/PG16, we performed gp120 sequence alignment analyses. We focused on residues 154-184 of V1V2 (HXB2-relative residue numbering), covering the entire PG9 epitope [15,40–42] (Fig. 1b). We searched for the conservation of residues interacting with PG9 in CAP45 and ZM109 strains, including two glycosylated residues Asn156 or Asn173 (N-Gly156 or N-Gly173) and Asn160 (N-Gly160), and a stretch of cationic residues of strand C making specific electrostatic interactions with negatively charged residues on the complementary determining region 3 (CDR H3) of the PG9 heavy chain [40]. We completed this analysis by looking for the conservation of residues whose mutagenesis was shown to confer PG9 resistance in the context of JR-CSF [15] or ConC [42].

All sequences from group O and P primary isolates lack the N-Gly156 and the Tyr173 residue predicted to stabilize the positioning of N-Gly156. In addition, sequences of group O primary isolates possess an acidic residue at position 170 (Glu170) that could repel the negatively charged sulphated tyrosines of PG9. These observations could explain the resistance or low sensitivity of the group P and of most group O primary isolates to both PG9 and PG16. In contrast, residues essential for PG9 binding were conserved in the sequence of the PG9-sensitive group N primary isolate (YBF30) and for most of the available sequences of other group N primary isolates of the Los Alamos HIV sequence database (, except for N1_FR_2011 primary isolates whose sequence lacks N-Gly160 (Fig. 1b). This was confirmed by modeling the three-dimensional structure of the V1/V2 domain of YBF30 complexed with PG9 (see Figure, Supplemental Digital Content 2, N-Gly156 and 160 form major interactions with PG9. In addition, interactions between strand C of YBF30 and the CDR H3 of PG9 are made by side-chains of cationic lysines of YBF30 (Lys168, Lys169 and Lys170) forming electrostatic interactions with negatively charged residues of PG9 including sulphated tyrosines Tyr100G, Tyr100H and Asp100I.

The PG9 resistance of the intergroup M/O recombinant strain RBF208 could be explained by the lack of the Tyr173 residue predicted to stabilize the positioning of N-Gly156. In contrast the group M strains BIG and FRO were PG9 resistant albeit the key residues were identical or similar to those of the susceptible strain JR-CSF. It is interesting to note that BIG remains sensitive to PG16, suggesting that residues outside of the structure identified-epitope could differentially affect the PG9 or PG16 sensitivity.

Back to Top | Article Outline


The identification of antigenic targets of bNAbs that would be conserved among highly divergent HIV variants could be useful in the conception of an HIV vaccine. A few studies have suggested that neutralizing epitopes might be conserved between group M and group O HIV-1 variants [34–36]. We wanted to revisit this question using a larger panel of isolates, including groups N and P viruses, as well as a large panel of human sera and several HuMo bNAbs [13–16]. We have confirmed that sera from HIV-1-infected individuals may share cross-neutralizing activities against group M, N, O and P primary HIV-1 isolates. Interestingly enough, the sera from group M-infected patients that were the most efficient at neutralizing group M viruses were also the most efficient to cross-neutralize the primary isolates from the three outgroups O, N and P, suggesting that trans-groups conserved epitopes were targeted.

We then asked whether the use of monoclonal antibodies would help to identify conserved antigenic targets of cross-group neutralization. Ferrantelli et al. [35] previously showed that b12, 2F5 and 4E10 neutralized a few group O isolates. We did not confirm this finding, as none of them neutralized the group O isolates or the prototypes of groups N and P. The discrepancy might be attributable to either the nature of the strains or of the neutralization assays. The recently described highly efficient HuMo bNAbs that target the CD4 binding site, VRC01, VRC03 and HJ16, did not neutralize any primary isolate of the three outgroups N, O and P.

In contrast, PG9 and PG16 demonstrated their capability to cross-neutralize various HIV-1 groups, even at a very low concentration. Two groups O primary isolates and the group N prototype strain YBF30 were neutralized by both HuMo bNAbs, YBF30 being particularly sensitive. It has been shown that PG9 and PG16 are quaternary–structure–preferring V1/V2-directed antibodies [15]. On the basis of the knowledge acquired through the structure of the V1/V2 domain of HIV-1 gp120 in complex with PG9 [40], the antigenic conservation of PG9 binding site between group M and particularly group N was explained by the conservation of key residues including two glycosylated residues, N156/N173 and N160, and a stretch of cationic residues of strand C of the four-strand β-sheet domain. In addition, we confirmed the interaction between PG9 and these key residues of the YBF30 V1/V2 by molecular modeling. The quaternary-structure-preferring V1/V2-directed antibodies are among the most common bNAbs in sera from infected donors [20,42]. We demonstrated in the present study that the targets of such antibodies are conserved between HIV-1 groups, at least group M and group N; group O at a lesser extent. Taken all together, these data suggest that the PG9/PG16 epitopes would be essential components for an HIV vaccine immunogen able to induce bNAbs.

Back to Top | Article Outline


We thank Pascal Poignard and IAVI for providing us with PG9 and PG16, Syria Laperche for providing us with the samples from blood donors, and Sylvie Brunet for her technical assistance. The Following reagents were obtained through the NIH AIDS Research and Reference Program, Division of AIDS, NIAID, NIH: VRC01 (catalog number 12033) and VRC03 (catalog number 12032) from Dr John Mascola, and HJ16 (catalog number 12138) from Dr Antonio Lanzavecchia. b12, 2G12, 4E10 and 2F5 were purchased from Polymun Scientific (Vienna, Austria).

M.B. and F.B. conceived and designed the study; M.B., E.-Y.G., and T.M. performed the experiments; J.C.P., E.A., and F.S. selected and characterized the samples related to groups N, O, and P; M.B., E.-Y.G., T.M., and F.B. analyzed the data; M.B. and F.B. wrote the manuscript. All authors received the manuscript and approved it for publication.

This work was supported by the Agence Nationale de Recherche sur le SIDA et les hépatites (ANRS, Paris, France). E.-Y.G. was supported by a postdoctoral fellowship from the ANRS.

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline


1. Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011; 473:463–469.
2. Korber B, Gnanakaran S. AIDS/HIV. Converging on an HIV vaccine. Science 2011; 333:1589–1590.
3. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413–444.
4. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010; 22:358–366.
5. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, et al. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term nonprogressors: prevalence and association with neutralizing activity. AIDS 2006; 20:1923–1930.
6. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83:7337–7348.
7. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200–206.
8. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2011; 481:81–84.
9. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011; 108:11181–11186.
10. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004; 189:2167–2173.
11. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951–954.
12. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5:e1000433.
13. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010; 5:e8805.
14. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466–470.
15. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285–289.
16. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856–861.
17. Binley JM, Ban YE, Crooks ET, Eggink D, Osawa K, Schief WR, Sanders RW. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 2010; 84:5637–5655.
18. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13:1032–1034.
19. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009; 83:1045–1059.
20. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010; 6:e1001028.
21. Gurtler LG, Hauser PH, Eberle J, von Brunn A, Knapp S, Zekeng L, et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994; 68:1581–1585.
22. Loussert-Ajaka I, Chaix ML, Korber B, Letourneur F, Gomas E, Allen E, et al. Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. J Virol 1995; 69:5640–5649.
23. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemee V, et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009; 15:871–872.
24. Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998; 4:1032–1037.
25. Vanden Haesevelde M, Decourt JL, De Leys RJ, Vanderborght B, van der Groen G, van Heuverswijn H, Saman E. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol 1994; 68:1586–1596.
26. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006; 313:523–526.
27. Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele BF, Liu W, et al. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006; 444:164.
28. Vessiere A, Rousset D, Kfutwah A, Leoz M, Depatureaux A, Simon F, Plantier JC. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J Acquir Immune Defic Syndr 2010; 53:107–110.
29. Barin F, Cazein F, Lot F, Pillonel J, Brunet S, Thierry D, et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003–2006. AIDS 2007; 21:2351–2353.
30. Roques P, Robertson DL, Souquiere S, Apetrei C, Nerrienet E, Barre-Sinoussi F, et al. Phylogenetic characteristics of three new HIV-1 N strains and implications for the origin of group N. AIDS 2004; 18:1371–1381.
31. Delaugerre C, De Oliveira F, Lascoux-Combe C, Plantier JC, Simon F. HIV-1 group N: travelling beyond Cameroon. Lancet 2011; 378:1894.
32. Vallari A, Bodelle P, Ngansop C, Makamche F, Ndembi N, Mbanya D, et al. Four new HIV-1 group N isolates from Cameroon: Prevalence continues to be low. AIDS Res Hum Retroviruses 2010; 26:109–115.
33. Yamaguchi J, McArthur CP, Vallari A, Coffey R, Bodelle P, Beyeme M, et al. HIV-1 Group N: evidence of ongoing transmission in Cameroon. AIDS Res Hum Retroviruses 2006; 22:453–457.
34. Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R, Janssens W, van der Groen G. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol 2000; 62:14–24.
35. Ferrantelli F, Kitabwalla M, Rasmussen RA, Cao C, Chou TC, Katinger H, et al. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies: implications for acquired immunodeficiency syndrome vaccine. J Infect Dis 2004; 189:71–74.
36. Nyambi PN, Nkengasong J, Peeters M, Simon F, Eberle J, Janssens W, et al. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. J Infect Dis 1995; 172:1228–1237.
37. Barin F, Brunet S, Brand D, Moog C, Peyre R, Damond F, et al. Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors. J Infect Dis 2004; 189:322–327.
38. Depatureaux A, Leoz M, De Oliveira F, Gueudin M, Damond F, Descamps D, et al. [Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data]. Med Mal Infect 2010; 40:669–676.
39. Braibant M, Xie J, Samri A, Agut H, Autran B, Barin F. Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain. Virology 2010; 405:81–92.
40. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011; 480:336–343.
41. Doria-Rose NA, Georgiev I, O’Dell S, Chuang GY, Staupe RP, McLellan JS, et al. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol 2012; 86:8319–8323.
42. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 2011; 85:3128–3141.

cross-group neutralization; HIV-1; PG9/PG16 epitopes

© 2013 Lippincott Williams & Wilkins, Inc.